Navigation Links
High-Efficiency Transfections Achieved with New Low-Toxicity Reagent


Nonliposomal formulation yields high efficiencies in a variety of transfection conditions

Brenda Rogers Paul Kotturi Natalia Novoradovskaya
Stratagene

Introducing foreign DNA into eukaryotic cells requires high-potency transfections, which demand superior quality transfection reagents that are efficient, have low toxicity, and work in the presence or absence of serum. We compared Stratagenes new GeneJammer transfection reagent to each of five leading transfection reagents. GeneJammer reagent, a new nonliposomal formulation, not only performed well in numerous cell lines, it also yielded high efficiencies in primary cells. When the viability of transfected cells was evaluated, GeneJammer reagent showed the highest number of living transfectants for all cell lines tested.

The demand for high-efficiency transfections is increasing, reflecting the expanding applications for transfection technology. Introducing foreign DNA into eukaryotic cells has become fundamental to analyzing gene function, producing recombinant gene products, and devising strategies for gene therapy. Successful transfection results rely on the transfection method and the capability of the transfection reagent.1,2,3 The ideal transfection reagent is characterized by specific attributes, such as high efficiency in a wide variety of cells in the presence or absence of serum and the inclusion of antibiotics, growth factors, or other supplements. Other important attributes include low toxicity, high stability, and easy handling.

Stratagenes new GeneJammer transfection reagent, which is a proprietary formulation of a polyamine and other components, offers these essential qualitites for achieving successful transfection results. We subjected GeneJammer reagent and five of the most popular transfection reagents to extensive analyses, comparing transfection perform
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors
2. Streamline Your siRNA Transfections
3. 140-Fold Increase of Protein Achieved in Pichia Fermentation
4. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
5. Brilliant Core Reagent Kits for QPCR and QRT-PCR
6. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
7. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. TransMessenger Transfection Reagent
11. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
Post Your Comments:
(Date:12/16/2009)... -- Martek Biosciences Corporation (Nasdaq: MATK ) today ... fiscal year ended October 31, 2009. Revenues for the ... million in the fourth quarter of fiscal 2008. Net ... for the fourth quarter of fiscal 2009, a 5% ... share, in last year,s fourth quarter. The fourth ...
(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...
(Date:12/16/2009)... supplement? InVitria has what scientists have been asking for! Zap-CHO ... the growth and productivity of CHO cells. Developed for scientists ... free, well defined and consistent recombinant CHO supplement. , ... ... 2009 -- Scientists working with CHO cells can now access ...
(Date:12/15/2009)... three Department of Energy (DOE) bio-energy research centers, has ... valuable intellectual property. , ... ... Surety, LLC , the leading provider of ... Joint BioEnergy Institute (JBEI), one of three Department of ...
Breaking Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5
... First Provider of Clinical Documentation Technology, ... ... Spheris has been selected as,the first awarded supplier of medical ... group purchasing organizations.,Under the parties, agreement, Spheris will provide Provista ...
... 2:00 pm ET on November 27, 2007, CAMBRIDGE, ... ) today announced its participation,in the Lazard Capital Markets ... 2007 at the New York Palace Hotel in New ... will be presenting at 2:00 pm ET on Tuesday, ...
... TORONTO, Nov. 20 /PRNewswire-FirstCall/ - ARIUS Research ... developing the next wave of,antibody therapeutics, today ... of Research, will present at the 14th ... Pereira will present on,ARIUS, non-traditional approach to ...
Other Biology Technology:Provista Awards Agreement to Spheris 2Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference 2ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 2
(Date:12/16/2009)... -- BIO-key International, Inc. (OTC Bulletin Board: ... solutions, today announced that SC Magazine, one ... named BIO-key International the 2009 Innovator of ... Biometrics. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) ... SC Magazine, "Biometric providers have been trying ...
(Date:12/15/2009)... GAINESVILLE, Fla. When treating devastating brain diseases such ... medical bags to find something to help a patient. ... to help the vast majority of patients with ataxia ... and coordination. , University of Florida neurologists are trying ... million Challenge grant from the National Institute of Neurological ...
(Date:12/15/2009)... mammoths and ancient American horses may have been ... years longer than previously thought. After plucking ancient ... team of researchers used cutting-edge techniques to uncover ... samples dated to between 7,600 and 10,500 calendar ... one population of these now-extinct mammals endured longer ...
Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head Product 26 Portfolio Strategy 13965 1PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head Product 26 Portfolio Strategy 13965 2 C O R R E C T I O N Clinical Therapeutics 13962 1 C O R R E C T I O N Clinical Therapeutics 13962 2 C O R R E C T I O N Clinical Therapeutics 13962 3 C O R R E C T I O N Clinical Therapeutics 13962 4 C O R R E C T I O N Clinical Therapeutics 13962 5Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 56715 1Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 56715 2
... release is available in Spanish . , ... has studied the origin of the mutation that causes Fatal Familiar ... is a high rate of carriers of this mutation 50%of ... Fatal Familiar Insomnia (FFI) is one of the diseases considered as ...
... HIGHLIGHTS BREAKTHROUGH RESEARCH IN UNDERSTANDING GENETIC AND SOCIOECONOMIC ... , Although racial and ethnic differences in treatment ... little is understood about the underlying causes and ... intractable problem. The American Association for Cancer Research ...
... An international group of scientists is linking nutrient pollution ... number of harmful algal blooms reported in recent years. When ... cause human respiratory and skin irritations and cause fish or ... edition of the journal Harmful Algae , scientists present ...
Other Biology News:Study on origin of mutation that causes fatal familiar insomnia 2Study on origin of mutation that causes fatal familiar insomnia 3American Association for Cancer Research hosts Science of Health Care Disparities Meeting 2
... are at least 20 structurally and functionally ... TGF-beta superfamily. BMPs were originally identified as ... They are also involved in embryogenesis and ... regulate the growth, differentiation, chemotaxis and apoptosis ...
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: